At a glance
ClinicalIndex Comparison RecordPhase 2Active· 49 enrolled
Drug / intervention
Tolcapone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo-Controlled Study of Tolcapone for OCD
In Brief
A Phase 2 clinical trial evaluating Tolcapone and Placebo for Obsessive-Compulsive Disorder and OCD. Active but no longer recruiting, targeting 49 participants across 1 site.
Detailed Summary
The primary aim of the present study is to examine the efficacy and safety of tolcapone in adults with moderate to severe OCD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObsessive-Compulsive Disorder, OCD
CountriesUnited States
Collaborators--
Timeline
Phase 2ActiveOverdue
2023202420252026
First PostedNov 2022
Enrollment StartJun 2023
Primary CompletionJun 2026
TodayJul 2026
First PostedNov 22, 2022
Enrollment StartJun 22, 2023
Primary CompletionJun 1, 2026
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 3.6 years ago
Interventions
Tolcaponedrug
catechol-O-methyl transferase inhibitor
Placebodrug
Pill that contains no medicine